Singapore IPOs April 13: Q1 US Listings Hit Zero as SGX Gains Appeal

Singapore IPOs are back in focus after LSEG data showed zero Singapore-registered companies listed in the US during Q1 2026, while three deals floated on SGX raised nearly US$800 million. Investors are weighing the US IPO slowdown, weaker post-listing performance, and tighter small-cap scrutiny against Singapore’s push to deepen its market. With MAS EQDP and a proposed Global Listing Board under discussion, the centre of gravity for new issues could tilt home this year, even as a 12-name US pipeline remains in play.

Q1 snapshot: Zero US listings, three on SGX

LSEG data cited by local media show no Singapore-registered companies listed in the US in Q1 2026, while three IPOs priced on SGX raised nearly US$800 million. This marks a clear tilt toward domestic venues for fresh capital. The shift follows a softer backdrop abroad and improving sponsorship at home, according to reporting from Zaobao source.

When new issues cluster on SGX, price discovery and post-IPO liquidity are more likely to concentrate locally. That can improve access to placements, analyst coverage, and trading hours that match Singapore investors. It also reduces FX and cross-border settlement frictions, which matter most for smaller tickets and short-term trading strategies around allocations and stagging potential.

US IPO slowdown and shifting incentives

The US IPO slowdown has been driven by weaker average post-IPO performance and stricter scrutiny of small caps. Issuers face higher costs, longer timelines, and a greater bar for profitability. For mid-cap and growth issuers from Singapore, this means a less certain debut path compared with listing at home, where peer benchmarks and investor outreach are more targeted.

Home-market listings can offer tighter valuation ranges, faster feedback from regional funds, and clearer aftermarket support. Boards also weigh time-to-market and disclosure complexity. If comparable companies already trade on SGX, underwriters can build books with more confidence. These factors, taken together, raise the appeal of SGX listings when global risk appetite is uneven.

What SGX is doing: EQDP and a Global Listing Board

Singapore is investing in market depth. MAS’s EQDP and related initiatives aim to improve research attention, liquidity quality, and issuer readiness. SGX is also pushing for greater sector diversity to broaden the investor base and make deal flow steadier across cycles, as highlighted by Business Times reporting source.

A proposed Global Listing Board has been discussed to attract international names and more secondary listings. If implemented, it could add recognisable companies to the tape, lift turnover, and provide stronger valuation anchors for local issuers. For investors, that means richer sector comps, deeper ETFs and index interest, and a healthier pipeline of follow-on offerings.

What to watch next: pipeline, sectors, liquidity

A 12-name US pipeline for 2026 remains, so a complete relocation of Singapore IPOs is not a given. Windows can reopen quickly. Watch volatility, deal-size mix, and first-day performance of early movers. If initial US prints stabilise and price inside ranges, cross-border interest from Singapore issuers could return in the second half.

Domestically, monitor pre-deal research, cornerstones, and free float. Strong cornerstones and reasonable floats often signal healthier trading. Also track how liquidity programs and market-maker activity support new listings in the first 90 days. If aftermarket spreads tighten and volumes rise, more issuers may choose SGX for primary listings.

Final Thoughts

For Singapore investors, the signal is clear: new money is finding its way to local boards. With Singapore IPOs showing renewed traction on SGX and the US IPO slowdown reducing cross-border draw, we should prepare for more prospectuses, earlier pre-marketing, and tighter bookbuilds at home. Practical steps include reviewing use of proceeds, lock-up terms, and free float, and comparing valuation to regional peers. Focus on sponsors with proven distribution and analysts who will publish quickly after listing. Set allocation and trading plans before debut day, and size positions for expected liquidity. If EQDP and broader listing reforms lift research and depth this year, the local IPO bid could strengthen further.

FAQs

What is driving the recent momentum in Singapore IPOs?

Three SGX deals in Q1 2026 raised nearly US$800 million while no Singapore-registered companies listed in the US. Weaker US post-IPO performance and tighter scrutiny of small caps reduced cross-border appeal. At the same time, Singapore is pushing market development, including MAS’s EQDP and proposals to attract more diverse listings, which can improve liquidity and research.

How does the US IPO slowdown affect Singapore investors?

With the US IPO slowdown, more issuers may choose SGX, concentrating price discovery and liquidity locally. That can improve access to allocations, research, and trading hours that fit Singapore. It also reduces FX and custody frictions for retail. Still, a 12-name US pipeline for 2026 means cross-border opportunities could return if conditions improve.

What is MAS EQDP and why does it matter?

MAS’s EQDP is part of Singapore’s equity market development efforts. While details vary by program, the goal is to support healthier listings by improving research attention, liquidity quality, and issuer readiness. For investors, better research coverage and tighter spreads can make new issues easier to value and trade in the first months after listing.

What should I check before applying for an SGX IPO?

Review use of proceeds, lock-up periods, and free float. Compare valuation with regional comps and stress-test earnings assumptions. Look for strong cornerstones and clear catalysts in the first year post-listing. Plan entry, exit, and position size based on expected liquidity and spreads. Read the prospectus and early research for risk factors and governance.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.